Wessely works in the most prestigious London units involved in psychiatric research. The GKT complex also encompasses the Institute of Psychiatry (IOP). The whole of Wessely’s department in the IOP is committed to, and working on, issues relating to the psychiatric aetiology of illness. He is also involved in the King’s College Centre for Risk Management (KCRM), which is researching the perceived health risks of mobile phones and their masts, with the view, no doubt, to finding that there are none. The IOP receives funding from, among others, Unilever, SmithKline Beecham, Pfizer, Novartis, NPS Pharmaceuticals; Lilly Industries Ltd. (manufacturers of Prozac), Hoescht Marion Roussel, Glaxo-SmithKline (Seroxat), Bristol Myers Squibb, Bayer, Zeneca and Wyeth. Professor Wessely has been employed or grant-aided by both the British Ministry of Defence and the US Defense Department. He has contributed to seminars and meetings at NATO on crisis management of public fears of terrorist incidents. His connections with the military clearly involve conflicts of interests, and his work on Gulf War syndrome is thus automatically more suspect than that of independent researchers. Professor Wessely has admitted to being an adviser to PRISMA Health, which was founded in 1999 and began establishing its programme in Europe and North America. Its head office and the corporate staff are based in Essen, Germany, and its president in the year 2000 was George F. Thoma, a German managing partner at Shearman & Sterling, a global law firm with more than 1,000 lawyers based in the world’s financial capitals. Representatives of the US government and the most powerful corporations of North America, such as Monsanto, have visited the company’s offices in New York. Thoma is a member of the company’s Mergers & Acquisitions Group, and practises primarily in the areas of corporate law, mergers and acquisitions, corporate restructuring and privatisations.